Department of Medicine, Division of Hematology and Oncology, Orlando Health Corp, Orlando, Florida, USA.
Division of Hematology and Oncology, UF Health Cancer Center-Orlando Health, Orlando, Florida, USA.
BMJ Case Rep. 2021 May 10;14(5):e241070. doi: 10.1136/bcr-2020-241070.
The approach to metastatic lung cancer has long been focused on palliation therapy and comfort care. Recently, significant subsets of patients who suffer from a limited form of the disease have shown curative outcomes. The oligometastatic disease theory was first introduced in 1995, and since has been applied to many solid tumours. In oligometastatic nonsmall cell lung cancer, current treatment strategies include surgery, radiation therapy and chemotherapy. There is evidence of astounding survival benefits in selected patients treated with immune checkpoint inhibitors. We present three cases with oligometastatic nonsmall cell lung cancer treated with pembrolizumab, an immune checkpoint inhibitor, and describe the outcomes. Immunotherapy with pembrolizumab appears to be an effective adjunctive treatment with low toxicity in oligometastatic nonsmall cell lung cancer.
转移性肺癌的治疗方法长期以来一直侧重于姑息治疗和舒适护理。最近，患有有限形式疾病的大量患者已经显示出治愈的结果。寡转移疾病理论于 1995 年首次提出，此后已应用于许多实体瘤。在寡转移性非小细胞肺癌中，目前的治疗策略包括手术、放射治疗和化疗。在接受免疫检查点抑制剂治疗的选定患者中，有令人惊讶的生存获益的证据。我们介绍了三例接受免疫检查点抑制剂派姆单抗治疗的寡转移性非小细胞肺癌患者，并描述了结果。派姆单抗的免疫治疗似乎是一种有效的辅助治疗方法，在寡转移性非小细胞肺癌中具有低毒性。
